Oncopharmpod

Running through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.

This week we look at the NEJM publication earlier this month (https://www.nejm.org/doi/full/10.1056/NEJMoa1817073) of E1912. Points of discussion include IGHV mutational status, PFS vs. OS as endpoints in CLL, the benefit of rituximab in addition to ibrutinib, and ibrutinib toxicity in younger vs. older CLL patients. (Also, apologies to my APPE student for dropping this Pod *after* your journal club on this paper.)

Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).

Darolutamide has been FDA-approved. We discuss its differences and similarities to other 2nd-generation anti-androgens (enzalutamide & apalutamide) - especially potential drug interactions!

Our Landmarks in #OncoPharm series returns to the breast cancer patient population to review the landmark 2008 NEJM article from Sparano et al (https://www.nejm.org/doi/full/10.1056/NEJMoa0707056) investigating the optimal taxane regimen to follow adjuvant AC.

A brief discussion on FDA's approval decision on selinexor and its possible role in therapy. Then, a more in-depth details on its MOA, dosing, and toxicity profile.

An overview of pain management principles in cancer patients. Topics covered include the role of NSAIDs, bisphosphonates, and opioids in treating or preventing pain. Also discussed: bowel regimens & opioid conversions.

The Foundations in #Oncopharm series returns with the story of a failed contraceptive candidate that became the first (?) targeted therapy for use in cancer. Tamoxifen's use, MOA, toxicities, and drug interactions are also discussed.

We open up the Ask #OncoPharm inbox to answer a listener question - What advice do you have before starting my PGY2 Oncology Pharmacy Residency?

Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)

A newly approved drug for relapsed/refractory diffuse large B-cell lymphoma is discussed as well as PBR.

Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan. *caveats apply

Discussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...

The Landmarks in #OncoPharm continues down its breast cancer-centric track with the landmark CALGB 9344 trial that established the role of paclitaxel in the adjuvant setting --> https://ascopubs.org/doi/pdf/10.1200/JCO.2003.02.063

The Landmarks in #OncoPharm series returns with a discussion of NSABP B-15, which established AC as a standard adjuvant chemo regimen for breast cancer --> (https://ascopubs.org/doi/abs/10.1200/JCO.1990.8.9.1483)

Running through updated FDA approvals from this month (ivosidenib, T-DM1, ramucirumab, avelumab/axitinib, & venetoclax/obinutuzumab) and how these approvals raise more questions.

The Foundations of OncoPharm returns with imatinib, the 1st TKI. Discussion includes its history (and how imatinib's Phase I study almost didn't happen), uses, and toxicity.

Discussion of 2 important malignant hematology updates: the NEJM publication of the 1st published results of CAR-T therapy in multiple myeloma and the FDA-approval of ivosidenib in frail AML patients (with IDH1 mutations).

Reviewing the REFLECT (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext) study and its take-home points on selecting an agent for advanced HCC.

Summary of erdafitinib's FDA-approval including dosing, MOA, toxicity, and (wait 'til the end) prevalence of FGFR mutations. Ifos. Eye-Phos.